Clinical Study for AL-CM

Second Affiliated Hospital, School of Medicine, Zhejiang University400 enrolled

Overview

In this study, patients diagnosed with Al-CM were selected to observe the effect of treatment and conduct long-term follow-up.

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Immunoglobulin Light Amyloidosis Cardiomyopathy

Interventions

current treatment of AL-CMDRUG

current treatment of AL-CM

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients aged 18-90 years, regardless of gender, diagnosed with Al-CM at the Second Affiliated Hospital of Zhejiang University School of Medicine; * Patients have the ability to understand the test, can cooperate with investigators. Exclusion Criteria: * Unable to understand or unwilling to fill in informed consent forms or follow visitors

Locations (1)

2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Hangzhou, Zhejiang, China

RECRUITING

Outcomes

Primary Outcomes

Primary Outcome

incidences of MACE-4(cardiovascular death, myocardial infarction, stroke and hospitalized unstable angina)

Time frame: 10 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.